Treatment of Neuronal Ceroid Lipofuscinosis Type 2 with Cerliponase Alfa: A Systematic Review and Single-Arm Meta-Analysis of Two Studies
Journal of Child Neurology · 2026
DOI: 10.1177/08830738251389180 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Child Neurology, 2026. Verfasst von Juliana Almeida Oliveira und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Federal University of Minas Gerais, Belo Horizonte, Brazil. Hauptthemen laut MEDLINE: Neuronal Ceroid-Lipofuscinoses, Recombinant Proteins, Tripeptidyl-Peptidase 1, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Background
Neuronal ceroid lipofuscinosis type 2 (CLN2) is a rare neurodegenerative disorder caused by CLN2 gene mutations, leading to ceroid lipofuscin accumulation and progressive neurodegeneration. Cerliponase alfa, a recombinant tripeptidyl peptidase-1, may improve aspects of disease progression, but common hypersensitivity and infusion reactions, along with a limited number of studies and lack of controlled trials, constrain the generalizability of these findings.
Purpose
This systematic review and single-arm meta-analysis aims to evaluate the efficacy and safety of cerliponase alfa in treating children with CLN2.
Methods
Following Cochrane and Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines, the protocol was registered in PROSPERO (CRD42024541000). We included prospective and retrospective cohorts of CLN2 patients treated with cerliponase alfa. A comprehensive search was conducted in PubMed, Embase, and Cochrane Central up to February 2024. Clinical outcomes and adverse effects were analyzed using a random effects model to compute pooled proportions with 95% CIs. Study quality was assessed with the Cochrane Risk of Bias tool for Non-randomized Studies.
Results
From 318 records, 3 observational studies with 55 patients were included. A Clinical Rating Scale score of 0 or 1 was seen in 24% of patients. Generalized tonic-clonic seizures occurred in 41%, and dystonia in 15%. Adverse events included pyrexia (60%), hypersensitivity (82.6%), anaphylaxis (3%), and infusion-associated reactions (18.31%). Significant heterogeneity was observed.
Conclusion
Cerliponase alfa may improve clinical outcomes in children with CLN2, though adverse effects might be prevalent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Federal University of Minas Gerais, Belo Horizonte, Brazil.
- Department of Medicine, King Edward Medical University, Karachi, Pakistan.
- Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan.
- Department of Medicine, King Edward Medical University, Lahore, Pakistan.
- Department of Medicine, Faculdade de Minas, Belo Horizonte, Brazil.
- Department of Neurology, University of Florida, Gainesville, USA.
ORCID-Profile: Juliana Almeida Oliveira
Zitieren
APA
Oliveira, J. A., Saddique, M. N., Qadri, M., Shahid, F., de Jesus, A. C. F. S., & Sarmento, F. P. (2026). Treatment of Neuronal Ceroid Lipofuscinosis Type 2 with Cerliponase Alfa: A Systematic Review and Single-Arm Meta-Analysis of Two Studies. Journal of Child Neurology. https://doi.org/10.1177/08830738251389180
Vancouver
Oliveira JA, Saddique MN, Qadri M, Shahid F, de Jesus ACFS, Sarmento FP. Treatment of Neuronal Ceroid Lipofuscinosis Type 2 with Cerliponase Alfa: A Systematic Review and Single-Arm Meta-Analysis of Two Studies. Journal of Child Neurology. 2026. doi:10.1177/08830738251389180
BibTeX
@article{Oliveira2026,
author = {Oliveira, Juliana Almeida and Saddique, Muhammad Nabeel and Qadri, Maria and Shahid, Fatima and de Jesus, Ana Clara Fonseca Souza and Sarmento, Filipe Pereira},
title = {Treatment of Neuronal Ceroid Lipofuscinosis Type 2 with Cerliponase Alfa: A Systematic Review and Single-Arm Meta-Analysis of Two Studies},
journal = {Journal of Child Neurology},
year = {2026},
doi = {10.1177/08830738251389180}
}
EUVIMED